Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A

Charcot-Marie-Tooth Disease, Type IA Clinical Trial

Official title:
Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A

Status Completed

Clinical Trial Summary

Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Charcot-Marie-Tooth disease (CMT) type 1A

Clinical Trial Description

It is the first in human (FIH), 3+3 design clinical trial to evaluate the safety and tolerability and determine the maximum tolerated dose (MTD) of EN001 (allogeneic umbilical cord-derived mesenchymal stem cells) in the treatment of Charcot-Marie-Tooth disease (CMT) type 1A. ;

Study Design

Related Conditions & MeSH terms

Charcot-Marie-Tooth Disease
Charcot-Marie-Tooth Disease, Type IA
Hereditary Sensory and Motor Neuropathy
Nerve Compression Syndromes
Tooth Diseases

Clinical Trial Details

NCT number	NCT05333406
Study type	Interventional
Source	ENCell
Contact
Status	Completed
Phase	Phase 1
Start date	February 22, 2022
Completion date	December 20, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03550300` - Muscle MRI in Charcot Mary Tooth Disease: a Prospective Cohort Study
Recruiting	`NCT05902351` - Natural History Study for Charcot Marie Tooth Disease
Active, not recruiting	`NCT03023540` - Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A	Phase 3
Completed	`NCT02982343` - BALTiC Study: A Feasibility Analysis of Home Based BALance Training in People With Charcot-Marie-Tooth Disease	N/A
Completed	`NCT03386266` - Biomarkers and Validation of Selected Outcome Measures (CMTNSmod)
Not yet recruiting	`NCT03397303` - Quantification of Nerve Stiffness in Neuropathies	N/A
Completed	`NCT00484510` - High Dose Ascorbic Acid Treatment of CMT1A	Phase 2/Phase 3